Overview

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus filgrastim in treating patients who have advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Docetaxel
Gemcitabine
Lenograstim